A Marabelle
Overview
Explore the profile of A Marabelle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
3375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roulleaux Dugage M, Lambotte O, Mariette X, Marabelle A
Ann Oncol
. 2025 Jan;
36(1):6-9.
PMID: 39755430
No abstract available.
2.
Westphalen C, Martins-Branco D, Beal J, Cardone C, Coleman N, Schram A, et al.
Ann Oncol
. 2024 Aug;
35(11):936-953.
PMID: 39187421
Background: Advances in precision oncology led to approval of tumour-agnostic molecularly guided treatment options (MGTOs). The minimum requirements for claiming tumour-agnostic potential remain elusive. Methods: The European Society for Medical...
3.
Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, Andre T, et al.
Ann Oncol
. 2024 May;
35(7):643-655.
PMID: 38777726
Background: POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint...
4.
Toulemonde E, Chevret S, Battistella M, Neidhardt E, Nardin C, Le Du F, et al.
Cancer Immunol Immunother
. 2023 Apr;
72(8):2649-2657.
PMID: 37067554
Trichoblastic carcinoma is a rare malignant cutaneous adnexal tumor with a risk of local invasion and distant metastasis. As of today, there is no consensus for the treatment of locally...
5.
Peyraud F, Guegan J, Bodet D, Nafia I, Fontan L, Auzanneau C, et al.
Ann Oncol
. 2022 Jul;
33(10):1041-1051.
PMID: 35850444
Background: The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do not derive benefits. Therefore, it is crucial to...
6.
OMalley D, Bariani G, Cassier P, Marabelle A, Hansen A, De Jesus Acosta A, et al.
Gynecol Oncol
. 2022 Jul;
166(2):245-253.
PMID: 35835611
Objective: Pembrolizumab demonstrated a clinically meaningful objective response rate in patients with previously treated, advanced MSI-H/dMMR endometrial cancer in the multicohort phase 2 KEYNOTE-158 study (ClinicalTrials.gov, NCT02628067). We present health-related...
7.
Maio M, Ascierto P, Manzyuk L, Motola-Kuba D, Penel N, Cassier P, et al.
Ann Oncol
. 2022 Jun;
33(9):929-938.
PMID: 35680043
Background: Pembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors in the phase II multicohort...
8.
Bessede A, Marabelle A, Guegan J, Danlos F, Cousin S, Peyraud F, et al.
Ann Oncol
. 2022 Jun;
33(9):909-915.
PMID: 35654248
Background: Acetaminophen (APAP) use has been associated with blunted vaccine immune responses. This study aimed to assess APAP impact on immunotherapy efficacy in patients with cancer. Patients And Methods: Exposure...
9.
Moreno V, Calvo E, Middleton M, Barlesi F, Gaudy-Marqueste C, Italiano A, et al.
Cancer Immunol Immunother
. 2022 May;
71(12):2985-2998.
PMID: 35596791
Background: We evaluated MK-4621, an oligonucleotide that binds and activates retinoic acid-inducible gene I (RIG-I), as monotherapy (NCT03065023) and in combination with the anti-programmed death 1 antibody pembrolizumab (NCT03739138). Patients...
10.
Loriot Y, Marabelle A, Guegan J, Danlos F, Besse B, Chaput N, et al.
Ann Oncol
. 2021 Aug;
32(11):1381-1390.
PMID: 34416362
Background: Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a crucial need to identify novel...